Try our Advanced Search for more refined results

In Re: Incretin Mimetics Products Liability Litigation

Track this case

Case Number:

3:13-md-02452

Court:

California Southern

Nature of Suit:

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Anthony J. Battaglia

Firms

Companies

Sectors & Industries:

November 16, 2015
Diabetes Drug MDL Ruling Helps Branded Cos. In Label Fights

A California federal court's decision for drugmakers in multidistrict litigation over their alleged failure to warn of their Type 2 diabetes drugs' potential to cause pancreas problems is among the first to clarify in detail that the U.S. Food and Drug Administration need not explicitly reject a heightened warning in order for branded-drug companies to beat labeling claims by injured patients.
November 09, 2015
Merck, Others Beat Warning Claims In Diabetes Drug MDL

Drugmakers including Merck defeated state law claims in multidistrict litigation accusing the companies of failing to warn patients of pancreas problems from Type 2 diabetes drugs when a California federal judge ruled Monday the U.S. Food and Drug Administration would have rejected the warnings on labels.
January 21, 2015
Cos. Say Rival Got Confidential Docs In Diabetes Drug MDL

Drugmakers including Eli Lilly & Co. argued Tuesday that the plaintiffs in multidistrict litigation over the alleged pancreatic risks of their diabetes drugs had violated a confidentiality order by showing confidential company documents to their expert, the chairman of what they claim is a competing pharmaceutical company.
October 07, 2014
Drugmakers Beat Doc Request In Diabetes Drug MDL

A California federal judge on Monday refused to force Eli Lilly and Co., Novo Nordisk Inc. and other drugmakers to turn over documents concerning pancreatic cancer events to plaintiffs in multidistrict litigation over diabetes drugs, ruling that the materials aren't relevant to the central disputes in the case.
August 27, 2014
Drugmakers Fight Doc Request In MDL Over Diabetes Drugs

Eli Lilly and Co., Novo Nordisk Inc. and other drug manufacturers urged a California federal court on Tuesday not to force them to produce documents related to pancreatic cancer events in multidistrict litigation over diabetes drugs, calling the request an "unreasonably burdensome fishing expedition."
February 27, 2014
FDA, EMA Back Safety Of Diabetes Drugs Targeted In MDL

The U.S. Food and Drug Administration and European Medicines Agency found no firm evidence Thursday that diabetes drugs made by Merck & Co. Inc., Novo Nordisk Inc. and others cause pancreatic cancer, as plaintiffs allege in multidistrict litigation against the drugmakers in California.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:

I forgot my password
I took a free trial but didn't get a verification email
How do I sign up for a newsletter?

Ask a question!